The latest announcement is out from Zevra Therapeutics (ZVRA).
Zevra Therapeutics has announced promising results from their Phase 2 clinical trial of KP1077, a treatment for Idiopathic Hypersomnia, showing the drug to be safe and well-tolerated. Patients experienced meaningful improvements in daytime sleepiness and other symptoms, with the trial providing essential data for advancing to a Phase 3 trial. The company is preparing to discuss next steps with the FDA, amidst caution about forward-looking statements, emphasizing the inherent risks and uncertainties in drug development.
See more data about ZVRA stock on TipRanks’ Stock Analysis page.
